Compare Illumina, Inc. (ILMN) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Newmont Corporation — how do they compare? Illumina, Inc. trades at $265 (market cap $39.95B), while Newmont Corporation trades at $117.4 (market cap $121.75B). The key difference: Newmont Corporation is far larger — about 3× Illumina, Inc.'s market cap, and Newmont Corporation pays a 0.9% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Newmont Corporation for 58 Days on average.
| ILMN | NEM | |
|---|---|---|
Market Cap | $39.95B | $121.75B |
Volume | 3,169,503 | 5,421,125 |
Sector | Health | Basic Materials |
52-Week High | $293.69 | $135.14 |
52-Week Low | $91.00 | $78.63 |
Typical Hold Time | 83 Days | 58 Days |
Enterprise Value | $41.31B | $118.34B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Newmont (NEM) trades at $113.54, down 2.45% on the day, amid a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has beaten earnings estimates for three consecutive quarters. Revenue grew to $22.67 billion in 2025 with a net income margin of 33.36%, while analyst consensus remains strongly bullish with a $136.83 price target.
The stock presents a compelling value opportunity with a P/E of 14.32 and robust profitability, though near-term technical weakness and gold price volatility pose risks. Upside potential is supported by operational improvements and shareholder returns, but investors must weigh macroeconomic factors affecting the gold sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
